Japan approves Rozebalamin (mecobalamin) for ALS treatment based on JETALS Phase III trial showing disease progression slowing.
Eisai Co., Ltd. has received approval in Japan for Rozebalamin (mecobalamin) to treat amyotrophic lateral sclerosis (ALS), based on the JETALS Phase III trial involving 130 patients. The trial demonstrated significant disease progression slowing compared to a placebo. While mecobalamin is already used for other conditions, its ALS mechanism is unclear; however, it may offer neuroprotective effects. This approval is notable as there are currently no curative treatments for ALS.
September 24, 2024
4 Articles